Pembrolizumab Granted 5 Additional Approvals in Japan

January 3, 2019 – The Japan Pharmaceuticals and Medical Devices Agency (PMDA) has approved pembrolizumab for 5 new indications, including melanoma, advanced microsatellite instability-high (MSI-H) tumors, and 3 expanded uses in advanced non–small cell lung cancer (NSCLC). “These 5 simultaneous approvals of pembrolizumab in Japan represent a significant achievement that involved extensive collaboration with the Japan Pharmaceuticals and Medical … (leggi tutto)